Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Technical Indicators

<< Previous

Bullboard Posts

Next >>

Comment by Maxmoeon Dec 22, 2020 11:29am

107 Views

Post# 32160866

RE:RE:Technical Indicators

If I recall correctly, NCIB purchases don't have same reporting rules as insiders. NCIB is calendar monthly I believe.

pabaloo wrote: Once it gets to cash it should bounce back. Insiders have been buying. I checked Sedi and can't find anything on the buybacks? Not even the 3000 they bought last quarter according to the conference call. Trevyent is going back to the fda In the new year and Trulance should be dealt with as well. Also looking for an announcement on Activis generic launch next week. Waiting to see.

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland